Medication-Assisted Treatment (MAT) Centers in Wyoming

Yes. Using other substances does not disqualify you from mat. Most Wyoming programs encourage honest disclosure at intake so the team can monitor for drug interactions, adjust the care plan, and refer you to parallel treatment for alcohol or stimulant use where indicated.

For methadone, once SAMHSA take-home criteria are met, the monthly OTP fee covers both in-clinic and take-home doses. For buprenorphine, the clinic fee typically covers the 30-day prescription filled at a Wyoming pharmacy. For long-acting naltrexone (Vivitrol), the monthly dose is administered at the visit and included in that visit fee.

Yes. Wyoming Medicaid covers Sublocade and Vivitrol as part of the MAT benefit; most plans require prior authorization documenting prior MAT adherence. Billing is handled by the Wyoming provider as a medical (not pharmacy) benefit.

Yes. Wyoming commercial plans cover Sublocade under the medical benefit (administered in clinic) with prior authorization documenting adherence to sublingual buprenorphine. The mat provider’s office handles the PA paperwork.

Yes. Faces & Voices of Recovery chapters, the American Society of Addiction Medicine (ASAM) regional sections, and Wyoming-based recovery community organizations advocate for patient rights. SAMHSA’s Recovery Community Services Program funds peer-led groups in most Wyoming counties.

Yes. Meta-analyses consistently find that patients who remain on MAT longer than 12 months have lower rates of relapse, infectious disease, and overdose death. Wyoming Medicaid-funded programs report improved retention with long-acting injectables compared to sublingual treatment.

For methadone and buprenorphine, continued opioid use at entry is expected — the medication is designed to stop use safely. For naltrexone, 7–14 opioid-free days are required first. Your Wyoming clinician will confirm the correct induction strategy at intake.

Follow-up within 3–7 days is standard after the first mat visit to confirm response and titrate the dose. Wyoming clinics may see stable patients weekly for the first month, then space visits out as stability is achieved.

Methadone carries overdose risk during induction when the dose is being titrated, particularly in combination with benzodiazepines, alcohol, or other sedatives. Buprenorphine has a ceiling effect that lowers overdose risk. Naltrexone does not cause opioid overdose. Your Wyoming clinic monitors risk closely.

Yes. Wyoming Medicaid covers MAT during pregnancy and for 12 months postpartum in Wyoming, with priority access and typically no cost-sharing. Pregnancy Medicaid applications are fast-tracked in most Wyoming counties — ask at intake.

Yes. Wyoming MAT programs routinely deliver individual counseling and group therapy by video. Telehealth counseling is reimbursed at parity by Wyoming Medicaid and most commercial insurers under current state and federal parity rules.

Buprenorphine and naltrexone prescriptions appear on pharmacy records like other prescriptions and are visible to dispensing pharmacies and authorized users of the PDMP. Methadone dispensed at an OTP is not reported to retail pharmacy systems.